

FluCov Influenza Activity Report #12

12 February 2024


Take home: continued elevated influenza activity in the Northern Hemisphere

- North America and Europe:** Influenza activity remains elevated with moderate to high activity in many U.S. states. In Europe, a mixed activity pattern was observed, characterized by increasing influenza activity in many countries (Denmark, France, Germany, UK) with moderate to high activity. In Italy, the Netherlands and Spain, influenza activity is decreasing but activity remains around 15% (Italy, Spain) and 50% (the Netherlands).
- Asia:** Influenza overall positivity rate decreased in China, but remained around 30% in week 05/2024 with moderate activity now reported in Northern China and medium activity reported in Southern China.
- Circulating virus:** While A/H3 and B/Victoria have predominated globally and in China, A/H1N1pdm09 has dominated circulation in most of the Northern Hemisphere. Presently, there are no documented cases of B-Yamagata
- Vaccine match:** Early indicators in the US suggest good vaccine match. France reports good match with A/H1N1pdm09, but mismatch in some percentage of A/H3 viruses.
- Influenza Viruses of Pandemic Potential:** On 9 Feb, a fatal H5N1 case in a 9-year-old boy was reported in Cambodia (Promed). A possible human infection with swine influenza A(H1N1)v in an adult male worker in a pig farm was reported in Spain on 29 Jan (DON). A(H1N1)v was reported from Brazil in an adult man with underlying medical conditions; he has fully recovered and has no history of exposure to pigs (DON).
- COVID hospitalizations:** Are decreasing in England, EU and the US, after a peak around the end of 2023.

Positive Influenza tests (%)


Note: France, Germany, Italy and UK positivity rate graph was last updated week 04/2024.

— Season 2023/2024
 — Season 2022/2023
 — Season 2021/2022
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen.

Data sources & details

China: China CDC

US: FluView (Clinical Laboratories)

NL & Spain: ERVISS

DK: WHO FluNET (non-sentinel)

All others: WHO FluNet (sentinel)

COVID: US (Department of Health and Human Services), EU (ERVISS), England (UKHSA)

A Nivel publication

FluCov team: Susanne Heemskerk, Bronke Boudewijns, Marco Del Riccio, Saverio Caini, John Paget.

[FluCov Influenza Activity Report #12: 12 February 2024](#). Netherlands, Utrecht: Nivel, 2024

Websites for more information

Project Website: <https://www.nivel.nl/en/flucov>

FluCoV Dashboard: <https://www.nivel.nl/en/flucov-dashboard>

Funding

The Nivel FluCov project is funded by Sanofi
